3. Epitelial ovarialcancer (EOC): Eggstokk-, eggleder- og bukhinnekreft

Aletti, G. D., Eisenhauer, E. L., Santillan, A., Axtell, A., Aletti, G., Holschneider, C., Chi, D. S., Bristow, R. E., & Cliby, W. A. (2011). Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecologic Oncology, 120(1), 23-8.

Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., ... Mitchell, G. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30(21), 2654-63.

Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., ... Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117-30.

Ashley, C., Dunleavy, A. (2019). The renal drug handbook: the ultimate prescribing guide for renal practitioners. CRC Press.

Barakat, R., Hensley, M. L., Bhaskaran, D., Rastogi, P., Korytowsky, B., Boyd, J., Robson, M., & Offit, K. (2002). Prophylactic Oophorectomy in Patients at Risk for Hereditary Ovarian Carcinoma. Gynecologic Oncology, 84(3), 482.

Barbolina, M. V. (2018). Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma. Cancers, 10(11)

Bast, R. C. ,. J., Siegal, F. P., Runowicz, C., Klug, T. L., Zurawski, V. R. ,. J., Schonholz, D., Cohen, C. J., & Knapp, R. C. (1985). Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecologic Oncology, 22(1), 115-20.

Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006). Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 102(3), 432-9.

Blackledge, G., Lawton, F., Redman, C., & Kelly, K. (1989). Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. British Journal of Cancer, 59(4), 650-653.

Bolton, K. L., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S. J., Karlan, B. Y., Lambrechts, D., Despierre, E., ... Pharoah, P. D. (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307(4), 382-90.

Bookman, M. A. (2010). The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Annals of Oncology, 21 Suppl 7, vii211-17.

Bristow, R. E., & Chi, D. S. (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology, 103(3), 1070-1076.

Bristow, R. E., Santillan, A., Diaz-Montes, T. P., Gardner, G. J., Giuntoli, R. L. ,. 2., Meisner, B. C., Frick, K. D., & Armstrong, D. K. (2007). Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer, 109(8), 1513-22.

Brohet, R. M., Goldgar, D. E., Easton, D. F., Antoniou, A. C., Andrieu, N., Chang-Claude, J., Peock, S., Eeles, R. A., ... Rookus, M. A. (2007). Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of Clinical Oncology, 25(25), 3831-3836.

Buamah, P. K., Rake, M. O., Drake, S. R., & Skillen, A. W. (1990). Serum CA 12-5 concentrations and CA 12-5/CEA ratios in patients with epithelial ovarian cancer. Journal of Surgical Oncology, 44(2), 97-99.

Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., ... Liang, S. X. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365(26), 2473-83.

Camara, O., & Sehouli, J. (2009). Controversies in the management of ovarian cancer--pros and cons for lymph node dissection in ovarian cancer. Anticancer Research, 29(7), 2837-2843.

Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609-15.

Champer, M., Huang, Y., Hou, J. Y., Tergas, A. I., Burke, W. M., Hillyer, G. C., Ananth, C. V., Neugut, A. I., ... Wright, J. D. (2018). Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecologic Oncology, 148(1), 19-27.

Chan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., & Bell, J. (2010). The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecologic Oncology, 116(3), 301-6.

Chi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., ... Barakat, R. R. (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecologic Oncology, 103(2), 559-64.

Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B. G., Fujiwara, K., ... Mannel, R. S. (2017). Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 18(6), 779-791.

Coleman, R. L., Spirtos, N. M., Enserro, D., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Kim, J. W., Park, S. Y., ... Mannel, R. S. (2019). Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. New England Journal of Medicine, 381(20), 1929-1939.

Collaborative Group on Epidemiological Studies of Ovarian Cancer (2012). Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Medicine, 9(4), e1001200.

Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral, V., Doll, R., Hermon, C., Peto, R., & Reeves, G. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371(9609), 303-314.

Collinson, F., Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M., Ledermann, J., Colombo, N., ... ICON1 collaborators (2014). Optimal treatment of early-stage ovarian cancer. Annals of Oncology, 25(6), 1165-71.

Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., ... Poveda, A. (2023). INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. British Journal of Cancer, 128(8), 1503-1513.

Colombo, N., Sessa, C., Bois, A. d., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., ... Querleu, D. (2019). ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer, 29(4), 728-760.

Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., ... Esmo–Esgo Ovarian Cancer Consensus Conference Working Group (2019). ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Annals of Oncology, 30(5), 672-705.

Coticchia, C. M., Yang, J., & Moses, M. A. (2008). Ovarian cancer biomarkers: current options and future promise. Journal of the National Comprehensive Cancer Network : JNCCN, 6(8), 795-802.

Crijnen, T. E. M., Janssen-Heijnen, M. L. G., Gelderblom, H., Morreau, J., Nooij, M. A., Kenter, G. G., & Vasen, H. F. A. (2005). Survival of patients with ovarian cancer due to a mismatch repair defect. Familial Cancer, 4(4), 301-305.

Crum, C. P., Drapkin, R., Miron, A., Ince, T. A., Muto, M., Kindelberger, D. W., & Lee, Y. (2007). The distal fallopian tube: a new model for pelvic serous carcinogenesis. Current Opinion in Obstetrics and Gynecology, 19(1), 3-9.

Cummings, S., Roman, S. S., Saam, J., Bernhisel, R., Brown, K., Lancaster, J. M., & Usha, L. (2021). Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. Journal of ovarian research, 14(1), 61.

de Hullu, J. A. (2020-2040). TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention (TUBA-WISP-II) (NCT04294927). Hentet fra https://clinicaltrials.gov/ct2/show/NCT04294927

Didar, H., Farzaneh, F., Najafiarab, H., Namakin, K., Gohari, K., Sheidaei, A., & Ramezani, S. (2023). Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis. Current Medical Research and Opinion, 39(6), 901-910.

Domchek, S., & Kaunitz, A. M. (2016). Use of systemic hormone therapy in BRCA mutation carriers. Menopause, 23(9), 1026-1027.

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., Garber, J. E., Neuhausen, S. L., ... Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975.

du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115(6), 1234-44.

Dørum, A., Heimdal, K., Løvslett, K., Kristensen, G., Hansen, L. J., Sandvei, R., Schiefloe, A., Hagen, B., ... Møller, P. (1999). Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstetricia et Gynecologica Scandinavica, 78(10), 906-911.

Dørum, A., Tonstad, S., Liavaag, A. H., Michelsen, T. M., Hildrum, B., & Dahl, A. A. (2008). Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecologic Oncology, 109(3), 377-83.

Evans, D. G. R., Clayton, R., Donnai, P., Shenton, A., & Lalloo, F. (2009). Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. European Journal of Human Genetics, 17(11), 1381-1385.

Fader, A. N. (2019-2028). Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [pågående studie] (NCT04095364). Hentet fra https://clinicaltrials.gov/study/NCT04095364

Fader, A. N., Gien, L. T., Miller, A., Covens, A., & Gershenson, D. M. (2021). A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum. Journal of Clinical Oncology, 39(15 suppl), TPS5601.

Fathalla, M. F. (1971). Incessant ovulation--a factor in ovarian neoplasia?. Lancet, 2(7716), 163-163.

Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., ... Scambia, G. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of Clinical Oncology, 26(6), 890-6.

Finch, A. P. M., Lubinski, J., Møller, P., Singer, C. F., Karlan, B., Senter, L., Rosen, B., Maehle, L., ... Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15), 1547-53.

Flaum, N., Crosbie, E. J., Edmondson, R. J., Smith, M. J., & Evans, D. G. (2020). Epithelial ovarian cancer risk: A review of the current genetic landscape. Clinical Genetics, 97(1), 54-63.

Forstner, R., Sala, E., Kinkel, K., & Spencer, J. A. (2010). ESUR guidelines: ovarian cancer staging and follow-up. European Radiology, 20(12), 2773-80.

Fotopoulou, C., Planchamp, F., Aytulu, T., Chiva, L., Cina, A., Ergönül, Ö., Fagotti, A., Haidopoulos, D., ... Campbell, J. (2021). European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. International Journal of Gynecological Cancer, 31(9), 1199-1206.

Friebel, T. M., Domchek, S. M., & Rebbeck, T. R. (2014). Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. Journal of the National Cancer Institute, 106(6), dju091.

Gaarenstroom, K. N., van der Hiel, B., Tollenaar, R. A. E. M., Vink, G. R., Jansen, F. W., van Asperen, C. J., & Kenter, G. G. (2006). Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. International Journal of Gynecological Cancer, 16 Suppl 1, 54-59.

Garcia Garcia, Y., de Juan Ferré, A., Mendiola, C., Barretina-Ginesta, M. P., Gaba Garcia, L., Santaballa Bertrán, A., Bover Barcelo, I., Gil-Martin, M., ... Gonzalez Martin, A. (2019). Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. International Journal of Gynecological Cancer, 29(6), 1050-1056.

Gatius, S., Matias Guiu, X., & Davidson, B. (2024). Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium. Virchows Archiv, 484(2), 339-351.

Gershenson, D. M., Bodurka, D. C., Coleman, R. L., Lu, K. H., Malpica, A., & Sun, C. C. (2017). Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. Journal of Clinical Oncology, 35(10), 1103-1111.

Giede, K. C., Kieser, K., Dodge, J., & Rosen, B. (2005). Who should operate on patients with ovarian cancer? An evidence-based review. Gynecologic Oncology, 99(2), 447-61.

Gill, S. E., McGree, M. E., Weaver, A. L., Cliby, W. A., & Langstraat, C. L. (2017). Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecologic Oncology, 144(2), 266-273.

Goff, B. A., Mandel, L. S., Drescher, C. W., Urban, N., Gough, S., Schurman, K. M., Patras, J., Mahony, B. S., & Andersen, M. R. (2007). Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer, 109(2), 221-7.

Goff, B. A., Sainz de la Cuesta, R., Muntz, H. G., Fleischhacker, D., Ek, M., Rice, L. W., Nikrui, N., Tamimi, H. K., ... Fuller, A. F. ,. J. (1996). Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecologic Oncology, 60(3), 412-7.

González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., ... ESMO Guidelines Committee (2023). Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(10), 833-848.

González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., ... Monk, B. J. (2019). Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 381(25), 2391-2402.

Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic Oncology, 95(1), 1-8.

Gore, M., Hackshaw, A., Brady, W. E., Penson, R. T., Zaino, R., McCluggage, W. G., Ganesan, R., Wilkinson, N., ... Gershenson, D. M. (2019). An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecologic Oncology, 153(3), 541-548.

Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990). Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecologic Oncology, 36(2), 207-211.

Gore, M. E., Hackshaw, A., Brady, W. E., Penson, R. T., Zaino, R. J., McCluggage, W. G., & Ganesan, R. (2015). Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).. Journal of Clinical Oncology, 33(SUPPL.), abstract 5528.

Gouy, S., Saidani, M., Maulard, A., Faron, M., Bach-Hamba, S., Bentivegna, E., Leary, A., Pautier, P., ... Morice, P. (2017). Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecologic oncology reports, 22, 21-25.

Grabowski, J. P., Harter, P., Heitz, F., Pujade-Lauraine, E., Reuss, A., Kristensen, G., Ray-Coquard, I., Heitz, J., ... du Bois, A. (2016). Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic Oncology, 140(3), 457-62.

Grindedal, E. M., Renkonen-Sinisalo, L., Vasen, H., Evans, G., Sala, P., Blanco, I., Gronwald, J., Apold, J., ... Moller, P. (2010). Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 47(2), 99-102.

Hankinson, S. E., Hunter, D. J., Colditz, G. A., Willett, W. C., Stampfer, M. J., Rosner, B., Hennekens, C. H., & Speizer, F. E. (1993). Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA, 270(23), 2813-8.

Hanley, G. E., McAlpine, J. N., Kwon, J. S., & Mitchell, G. (2015). Opportunistic salpingectomy for ovarian cancer prevention. Gynecologic oncology research and practice, 2, 5.

Harmsen, M. G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A. H., Prins, J. B., Bulten, J., Teerenstra, S., Adang, E. M., ... de Hullu, J. A. (2015). Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 15, 593.

Harrison, M. L., Jameson, C., & Gore, M. E. (2008). Mucinous ovarian cancer. International Journal of Gynecological Cancer, 18(2), 209-14.

Harter, P., Sehouli, J., Lorusso, D., Reuss, A., Vergote, I., Marth, C., Kim, J. W., Raspagliesi, F., ... Bois, A. D. (2017). LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. Journal of Clinical Oncology, 35(15_suppl), 5500.

Harter, P., Sehouli, J., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Mosgaard, B. J., ... du Bois, A. (2021). Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 385(23), 2123-2131.

Hartmann, L. C., & Lindor, N. M. (2016). The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. New England Journal of Medicine, 374(5), 454-468.

Heemskerk-Gerritsen, B. A. M., Seynaeve, C., van Asperen, C. J., Ausems, M. G. E. M., Collée, J. M., van Doorn, H. C., Gomez Garcia, E. B., Kets, C. M., ... Ovarian Cancer Research Group, ,. N. (2015). Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Journal of the National Cancer Institute, 107(5), djv033.

Heitz, F., Harter, P., Ataseven, B., Heikaus, S., Schneider, S., Prader, S., Bommert, M., Fisseler-Eckhoff, A., ... du Bois, A. (2018). Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. Annals of Surgical Oncology, 25(7), 2053-2059.

Helder-Woolderink, J. M., Blok, E. A., Vasen, H. F., Hollema, H., Mourits, M. J., & De Bock, G. H. (2016). Ovarian cancer in Lynch syndrome; a systematic review. European Journal of Cancer, 55, 65-73.

Hermsen, B. B. J., Olivier, R. I., Verheijen, R. H. M., van Beurden, M., de Hullu, J. A., Massuger, L. F., Burger, C. W., Brekelmans, C. T., ... Rookus, M. A. (2007). No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. British Journal of Cancer, 96(9), 1335-1342.

Hess, V., A'Hern, R., Nasiri, N., King, D. M., Blake, P. R., Barton, D. P. J., Shepherd, J. H., Ind, T., ... Gore, M. E. (2004). Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. Journal of Clinical Oncology, 22(6), 1040-1044.

Hogg, R., & Friedlander, M. (2004). Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. Journal of Clinical Oncology, 22(7), 1315-1327.

Huang, J., Chan, W. C., Ngai, C. H., Lok, V., Zhang, L., Lucero-Prisno, D. E. ,. 3., Xu, W., Zheng, Z. J., ... On Behalf Of Ncd Global Health Research Group Of Association Of Pacific Rim Universities, A. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14(9), 2230.

Hunn, J., & Rodriguez, G. C. (2012). Ovarian cancer: etiology, risk factors, and epidemiology. Clinical Obstetrics and Gynecology, 55(1), 3-23.

ICCR (2021). Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Histopathology Reporting Guide (Version 2.0). Sydney: International Collaboration on Cancer Reporting. Hentet fra https://www.iccr-cancer.org/wp-content/uploads/2022/02/ICCR-Ovary-2nd-edn-v1-bookmark.pdf

Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., Bernard, L., Maisonneuve, P., & Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer, 46(12), 2275-2284.

Itamochi, H., Kigawa, J., & Terakawa, N. (2008). Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Science, 99(4), 653-8.

Jacquet, P., & Sugarbaker, P. H. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treatment and Research, 82, 359-374.

Jiang, R., Feng, Y., Chen, Y., Cheng, X., Shi, T., Gao, W., Jia, H., Jiang, S., ... Zang, R. (2024). Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nature Medicine, 30(8), 2181-2188.

Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., ... Swart, A. (2015). Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet, 386(9990), 249-257.

Kehoe, S. M., & Kauff, N. D. (2007). Screening and prevention of hereditary gynecologic cancers. Seminars in Oncology, 34(5), 406-10.

Kessous, R., Laskov, I., Abitbol, J., Bitharas, J., Yasmeen, A., Salvador, S., Lau, S., & Gotlieb, W. H. (2017). Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 144(3), 474-479.

Ketabi, Z., Bartuma, K., Bernstein, I., Malander, S., Grönberg, H., Björck, E., Holck, S., & Nilbert, M. (2011). Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecologic Oncology, 121(3), 462-5.

Kotsopoulos, J., & Narod, S. A. (2020). Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. International Journal of Cancer, 147(5), 1245-1251.

Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K., Mooij, T. M., Roos-Blom, M., Jervis, S., van Leeuwen, F. E., ... Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402-2416.

Kurman, R. J., & Shih Ie, M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology, 34(3), 433-43.

Kurman, R. J., & Shih Ie, M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Human Pathology, 42(7), 918-31.

Kurnit, K. C., & Frumovitz, M. (2022). Primary mucinous ovarian cancer: options for surgery and chemotherapy. International Journal of Gynecological Cancer,

Kurnit, K. C., Sinno, A. K., Fellman, B. M., Varghese, A., Stone, R., Sood, A. K., Gershenson, D. M., Schmeler, K. M., ... Frumovitz, M. (2019). Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstetrics and Gynecology, 134(6), 1253-1259.

Kus, F., Guven, D. C., Yildirim, H. C., Chalabiyev, E., Akyildiz, A., Tatar, O. D., Sahin, Y. B., Ileri, S., ... Arik, Z. (2023). KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer. Biomarkers in Medicine, 17(7), 379-389.

Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., ... Velculescu, V. E. (2017). High grade serous ovarian carcinomas originate in the fallopian tube. Nature communications, 8(1), 1093.

Lakhani, S. R., Manek, S., Penault-Llorca, F., Flanagan, A., Arnout, L., Merrett, S., McGuffog, L., Steele, D., ... Easton, D. F. (2004). Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clinical Cancer Research, 10(7), 2473-81.

Langmar, Z., Nemeth, M., Vlesko, G., Kiraly, M., Hornyak, L., & Bosze, P. (2011). HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma. European Journal of Gynaecological Oncology, 32(6), 605-10.

Larsen, I. K. (2018). Cancer in Norway 2017: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2023). Cancer in Norway 2022: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Lawrie, T. A., Winter-Roach, B. A., Heus, P., & Kitchener, H. C. (2015). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. The Cochrane database of systematic reviews, 2015(12), Cd004706.

Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., ... Matulonis, U. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366(15), 1382-92.

Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., ... Fagotti, A. (2024). ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Annals of Oncology, 35(3), 248-266.

Liavaag, A. H., Dørum, A., Fosså, S. D., Trope, C., & Dahl, A. A. (2007). Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?. Journal of Clinical Oncology, 25(15), 2049-56.

Lindemann, K., Gibbs, E., Åvall-Lundqvist, E., dePont Christensen, R., Woie, K., Kalling, M., Auranen, A., Grenman, S., ... Kristensen, G. (2017). Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). British Journal of Cancer, 116(4), 455-463.

Lobo, R. A. (2007). Surgical menopause and cardiovascular risks. Menopause, 14(3 Pt 2), 562-6.

Madalinska, J. B., van Beurden, M., Bleiker, E. M., Valdimarsdottir, H. B., Hollenstein, J., Massuger, L. F., Gaarenstroom, K. N., Mourits, M. J., ... Aaronson, N. K. (2006). The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. Journal of Clinical Oncology, 24(22), 3576-82.

Mahner, S., Eulenburg, C., Staehle, A., Wegscheider, K., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., ... du Bois, A. (2013). Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer, 49(1), 142-149.

Marchetti, C., Kristeleit, R., McCormack, M., Mould, T., Olaitan, A., Widschwendter, M., MacDonald, N., & Ledermann, J. A. (2017). Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecologic Oncology, 144(1), 57-60.

Markman, M., Blessing, J., Rubin, S. C., Connor, J., Hanjani, P., & Waggoner, S. (2006). Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology, 101(3), 436-40.

Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., ... Antoniou, A. C. (2012). Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 21(1), 134-47.

McCluggage, W. G. (2021). Progress in the pathological arena of gynecological cancers. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 155 Suppl 1(Suppl 1), 107-114.

Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., ... Engot-Ov Nova Investigators (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine, 375(22), 2154-2164.

Mizuno, M., Kajiyama, H., Shibata, K., Mizuno, K., Yamamuro, O., Kawai, M., Nakanishi, T., Nagasaka, T., & Kikkawa, F. (2012). Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?. International Journal of Gynecological Cancer, 22(7), 1143-9.

Monk, B. J., Barretina-Ginesta, M. P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M. R., McCormick, C. C., Lorusso, D., ... González-Martín, A. (2024). Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology, 35(11), 981-992.

Monk, B. J., Herzog, T. J., & Tewari, K. S. (2016). Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Current Pharmaceutical Design, 22(30), 4717-4728.

Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., ... DiSilvestro, P. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 379(26), 2495-2505.

Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., Dinan, M., McBroom, A. J., ... Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. Journal of Clinical Oncology, 31(33), 4188-4198.

Morice, P., Scambia, G., Abu-Rustum, N. R., Acien, M., Arena, A., Brucker, S., Cheong, Y., Collinet, P., ... Grynberg, M. (2024). Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. The Lancet. Oncology, 25(11), e602-e610.

Muallem, M. Z., Gasimli, K., Richter, R., Almuheimid, J., Nasser, S., Braicu, E. I., & Sehouli, J. (2015). AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer. Anticancer Research, 35(6), 3423-3429.

Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R. ,. J., ... Secord, A. A. (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology, 25(19), 2811-8.

Mutch, D. G., & Prat, J. (2014). 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecologic Oncology, 133(3), 401-4.

Møller, P., Seppälä, T. T., Bernstein, I., Holinski-Feder, E., Sala, P., Gareth Evans, D., Lindblom, A., Macrae, F., ... Capella, G. (2018). Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 67(7), 1306-1316.

Nakamura, K., Banno, K., Yanokura, M., Iida, M., Adachi, M., Masuda, K., Ueki, A., Kobayashi, Y., ... Aoki, D. (2014). Features of ovarian cancer in Lynch syndrome (Review). Molecular and clinical oncology, 2(6), 909-916.

Nasjonalt konsensusmøte, Vilming, B. (2023). Forslag til flytdiagram Presentert på: Nasjonalt konsensusmøte: PARP hemmere i første linje, arrangert 09.02.2023 av Nasjonal kompetansetjeneste for Gynekologisk kreft ved Pr. Kristina Lindemann.

Nasjonalt kvalitetsregister for gynekologisk kreft (2024). Årsrapport 2023: resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for gynekologisk kreft Oslo: Kreftregisteret. Hentet fra https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2024/arsrapport-2023-nasjonalt-kvalitetsregister-for-gynekologisk-kreft.pdf

NCCN (2014). Guidelines for familial high-risk assessment breast and ovarian cancer Fort Washington, PA: National Comprehencive Cancer Network.

Nebgen, D. R., Hurteau, J., Holman, L. L., Bradford, A., Munsell, M. F., Soletsky, B. R., Sun, C. C., Chisholm, G. B., & Lu, K. H. (2018). Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecologic Oncology, 150(1), 79-84.

Nederlandse Vereniging voor Obstetrie en Gynaecologie (2015). Erfelijk en Familiair Ovariumcarcinoom [Hereditary and Familial Ovarian Carcinoma] Utrecht: Federatie Medisch Specialisten. Hentet fra https://richtlijnendatabase.nl/richtlijn/erfelijk_en_familiair_ovariumcarcinoom/erfelijk_en_familiair_ovariumcarcinoom_algemeen.html

Niloff, J. M., Knapp, R. C., Schaetzl, E., Reynolds, C., & Bast, R. C. ,. J. (1984). CA125 antigen levels in obstetric and gynecologic patients. Obstetrics and Gynecology, 64(5), 703-7.

NorPreM (2024). Nasjonal initiativ for å fremme presisjonsdiagnostikk innenfor gynekologisk kreft [s.l.]: Nasjonalt kompetansenettverk for persontilpasset medisin. Hentet fra https://norprem.no/wp-content/uploads/2024/11/Gyn.kreft-rapport-ferdigstilt.pdf

Oguri, T., Shimokata, T., Ito, I., Yasuda, Y., Sassa, N., Nishiyama, M., Hamada, A., Hasegawa, Y., & Ando, Y. (2015). Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemotherapy and Pharmacology, 76(1), 53-59.

Oseledchyk, A., Leitao, M. M. ,. J., Konner, J., O'Cearbhaill, R. E., Zamarin, D., Sonoda, Y., Gardner, G. J., Long Roche, K., ... Zivanovic, O. (2017). Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. Annals of Oncology, 28(12), 2985-2993.

Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Vuylsteke, P., ... Friedlander, M. (2015). Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet. Oncology, 16(1), 87-97.

Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., ... Gynecologic Oncology Group (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 21(17), 3194-3200.

Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., ... Mangioni, C. (2005). Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. Journal of the National Cancer Institute, 97(8), 560-566.

Parmar, M. K. B., Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., Wheeler, S., Swart, A. M., ... Icon and AGO Collaborators (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 361(9375), 2099-2106.

Pasanisi, P., Hédelin, G., Berrino, J., Chang-Claude, J., Hermann, S., Steel, M., Haites, N., Hart, J., ... Berrino, F. (2009). Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiology, Biomarkers and Prevention, 18(7), 2107-2113.

Paulsen, T., Kjaerheim, K., Kaern, J., Tretli, S., & Trope, C. (2006). Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. International Journal of Gynecological Cancer, 16 Suppl 1, 11-7.

Paulsen, T., Kærn, J., Kjærheim, K., Tropé, C., & Tretli, S. (2005). Symptoms and referral of women with epithelial ovarian tumors. International Journal of Gynaecology and Obstetrics, 88(1), 31-7.

Paulsen, T., Kærn, J., & Tropé, C. (2011). Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. Gynecologic Oncology, 122(1), 83-8.

Perren, T. J. (2016). Mucinous epithelial ovarian carcinoma. Annals of Oncology, 27(suppl_1), i53-i57.

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., ... Oza, A. M. (2011). A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365(26), 2484-96.

Phillips, A., Sundar, S., Singh, K., Nevin, J., Elattar, A., Kehoe, S., & Balega, J. (2018). Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology, 44(6), 760-765.

Piedimonte, S., Kim, R., Bernardini, M. Q., Atenafu, E. G., Clark, M., Lheureux, S., & May, T. (2022). Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology, 167(3), 417-422.

Piek, J. M., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort-Keesom, R. J., Menko, F. H., Gille, J. J., Jongsma, A. P., ... Verheijen, R. H. (2001). Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. The Journal of pathology, 195(4), 451-6.

Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., ... Perrone, F. (2011). Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. Journal of Clinical Oncology, 29(27), 3628-3635.

Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., ... Perrone, F. (2014). Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology, 15(4), 396-405.

Piver, M. S. (2002). Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecologic Oncology, 85(1), 9-17.

Powell, C. B., Chen, L. M., McLennan, J., Crawford, B., Zaloudek, C., Rabban, J. T., Moore, D. H., & Ziegler, J. (2011). Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. International Journal of Gynecological Cancer, 21(5), 846-51.

Prat, J., & FIGO Committee on Gynecologic Oncology (2014). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics, 124(1), 1-5.

Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., ... Ray-Coquard, I. (2014). Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of Clinical Oncology, 32(13), 1302-1308.

Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., ... du Bois, A. (2010). Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Journal of Clinical Oncology, 28(20), 3323-9.

Purdie, D. M., Bain, C. J., Siskind, V., Webb, P. M., & Green, A. C. (2003). Ovulation and risk of epithelial ovarian cancer. International Journal of Cancer, 104(2), 228-232.

Querleu, D., Planchamp, F., Chiva, L., Fotopoulou, C., Barton, D., Cibula, D., Aletti, G., Carinelli, S., ... duBois, A. (2017). European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 27(7), 1534-1542.

Raja, F. A., Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K., Vergote, I. B., Gonzalez-Martin, A., ... Ledermann, J. A. (2013). Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Annals of Oncology, 24(12), 3028-3034.

Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., Gentry-Maharaj, A., ... Gayther, S. A. (2015). Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 107(11)

Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., ... Harter, P. (2019). Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. New England Journal of Medicine, 381(25), 2416-2428.

Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80-87.

Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. Cancer biology & medicine, 14(1), 9-32.

Reikvam, D. H., Tveter, I., Bergersen, B., Haukeland, J. W. (09.10.2024). Kronisk hepatitt B. I: Infeksjonsmedisin (OUS) (Metodebok). [nettdokument]. Oslo: Oslo universitetssykehus. Hentet 09.12.2024 fra https://metodebok.no/index.php?action=topic&item=qUUHNAGr

Rouzier, R., Gouy, S., Selle, F., Lambaudie, E., Floquet, A., Fourchotte, V., Pomel, C., Colombo, P. E., ... Joly, F. (2017). Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer, 70, 133-142.

Rustin, G. J., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., ... Vermorken, J. (2004). Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute, 96(6), 487-8.

Schlappe, B. A., Zhou, Q. C., O'Cearbhaill, R., Iasonos, A., Soslow, R. A., Abu-Rustum, N. R., & Mueller, J. J. (2019). A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen. International Journal of Gynecological Cancer,

Sharma, A., & Menon, U. (2006). Screening for gynaecological cancers. European Journal of Surgical Oncology, 32(8), 818-24.

Shi, Q., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Sougklakos, I., Kerr, R., ... Iveson, T. (2017). Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Journal of Clinical Oncology, 35(18_suppl), LBA1.

Shi, T., Zhu, J., Feng, Y., Tu, D., Zhang, Y., Zhang, P., Jia, H., Huang, X., ... Zang, R. (2021). Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 22(4), 439-449.

Song, H., Dicks, E., Ramus, S. J., Tyrer, J. P., Intermaggio, M. P., Hayward, J., Edlund, C. K., Conti, D., ... Pharoah, P. D. (2015). Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 33(26), 2901-7.

Spiliopoulou, P., Hinsley, S., McNeish, I. A., Roxburgh, P., & Glasspool, R. (2021). Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31(7), 1037-1044.

Steenbeek, M. P., van Bommel, M. H. D., Bulten, J., Hulsmann, J. A., Bogaerts, J., Garcia, C., Cun, H. T., Lu, K. H., ... de Hullu, J. A. (2022). Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 40(17), 1879-1891.

Stirling, D., Evans, D. G., Pichert, G., Shenton, A., Kirk, E. N., Rimmer, S., Steel, C. M., Lawson, S., ... Porteous, M. E. (2005). Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. Journal of Clinical Oncology, 23(24), 5588-96.

Stockler, M. R., Hilpert, F., Friedlander, M., King, M. T., Wenzel, L., Lee, C. K., Joly, F., de Gregorio, N., ... Pujade-Lauraine, E. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 32(13), 1309-1316.

Stuart, G. C., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J., Marth, C., Thigpen, T., & Trimble, E. (2011). 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. International Journal of Gynecological Cancer, 21(4), 750-5.

Suszynska, M., Ratajska, M., & Kozlowski, P. (2020). BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. Journal of ovarian research, 13(1), 50.

Szczesny, W., Langseth, H., Myklebust, T. A., Kaern, J., Trope, C., & Paulsen, T. (2018). Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study. Acta Obstetricia et Gynecologica Scandinavica, 97(8), 956-965.

Sørensen, S. S., & Mosgaard, B. J. (2011). Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Danish Medical Bulletin, 58(11), A4331.

Tailor, A., Bourne, T. H., Campbell, S., Okokon, E., Dew, T., & Collins, W. P. (2003). Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound in Obstetrics and Gynecology, 21(4), 378-85.

Tan, D. S., Agarwal, R., & Kaye, S. B. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet. Oncology, 7(11), 925-34.

Thomassin-Naggara, I., Dabi, Y., Florin, M., Saltel-Fulero, A., Manganaro, L., Bazot, M., & Razakamanantsoa, L. (2024). O-RADS MRI SCORE: An Essential First-Step Tool for the Characterization of Adnexal Masses. Journal of magnetic resonance imaging : JMRI, 59(3), 720-736.

Timmerman, D., Planchamp, F., Bourne, T., Landolfo, C., du Bois, A., Chiva, L., Cibula, D., Concin, N., ... Fotopoulou, C. (2021). ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. International Journal of Gynecological Cancer, 31(7), 961-982.

Tingulstad, S., Hagen, B., Skjeldestad, F. E., Halvorsen, T., Nustad, K., & Onsrud, M. (1999). The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstetrics and Gynecology, 93(3), 448-52.

Toss, A., Tomasello, C., Razzaboni, E., Contu, G., Grandi, G., Cagnacci, A., Schilder, R. J., & Cortesi, L. (2015). Hereditary ovarian cancer: not only BRCA 1 and 2 genes. BioMed research international, 2015, 341723.

Trabert, B., Ness, R. B., Lo-Ciganic, W., Murphy, M. A., Goode, E. L., Poole, E. M., Brinton, L. A., Webb, P. M., ... Ovarian Cancer Association Consortium (2014). Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 106(2), djt431.

Trimbos, J. B., Parmar, M., Vergote, I., Guthrie, D., Bolis, G., Colombo, N., Vermorken, J. B., Torri, V., ... European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm (2003). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute, 95(2), 105-112.

Vasey, P. A., Atkinson, R., Coleman, R., Crawford, M., Cruickshank, M., Eggleton, P., Fleming, D., Graham, J., ... Kaye, S. B. (2001). Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. British Journal of Cancer, 84(2), 170-178.

Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., Gore, M. E., Kærn, J., ... Trope, C. G. (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, 357(9251), 176-82.

Vergote, I., Trope, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H., van der Burg, M. E., ... Reed, N. S. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363(10), 943-53.

Vermeulen, R. F. M., Beurden, M. V., Korse, C. M., & Kenter, G. G. (2017). Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric : the journal of the International Menopause Society, 20(3), 212-221.

Vernooij, F., Heintz, P., Witteveen, E., & van der Graaf, Y. (2007). The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecologic Oncology, 105(3), 801-12.

von Gruenigen, V. E., Huang, H. Q., Beumer, J. H., Lankes, H. A., Tew, W., Herzog, T., Hurria, A., Mannel, R. S., ... Fleming, G. (2017). Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 144(3), 459-467.

Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., ... Swisher, E. M. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032-7.

Watson, P., Bützow, R., Lynch, H. T., Mecklin, J. P., Järvinen, H. J., Vasen, H. F., Madlensky, L., Fidalgo, P., ... International Collaborative Group on, H. (2001). The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic Oncology, 82(2), 223-228.

Weinberger, V., Bednarikova, M., Cibula, D., & Zikan, M. (2016). Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management. Expert Review of Anticancer Therapy, 16(12), 1311-1321.

Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., Setiawan, V. W., Visvanathan, K., ... Tworoger, S. S. (2016). Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 34(24), 2888-98.

Wethington, S. L., Park, K. J., Soslow, R. A., Kauff, N. D., Brown, C. L., Dao, F., Otegbeye, E., Sonoda, Y., ... Gardner, G. J. (2013). Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). International Journal of Gynecological Cancer, 23(9), 1603-11.

WHO Classification of Tumours Editorial Board (2020). Female Genital Tumours. International Agency for Research on Cancer.

Winter, W. E. ,. 3., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., ... McGuire, W. P. (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology, 25(24), 3621-7.

Xu, K., Yang, S., & Zhao, Y. (2017). Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget, 8(1), 285-302.

Yedema, C. A., Kenemans, P., Wobbes, T., Thomas, C. M., Bon, G. G., Mulder, C., Voorhorst, F. J., Verstraeten, A. A., ... Hilgers, J. (1992). Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biology, 13(1-2), 18-26.